Search

Your search keyword '"Sarr AD"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Sarr AD" Remove constraint Author: "Sarr AD"
29 results on '"Sarr AD"'

Search Results

2. A metagenomic assessment of bacterial community in spices sold open-air markets in Saint-Louis, Senegal.

3. Time to deliver: report of the WHO Independent High-Level Commission on NCDs.

4. Building laboratory capacity to support HIV care in Nigeria: Harvard/APIN PEPFAR, 2004-2012.

5. N,N'-Dimethyl-ethylenediammonium dioxalatocuprate(II).

6. 1-(Thio-phen-2-yl)ethanone thio-semi-carbazone.

7. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

8. 4,6-Dimethyl-2-thioxo-1,2-dihydro-pyrimidin-3-ium chloride-thio-urea (1/1).

9. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.

10. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.

11. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.

12. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

13. Long-term intrapatient viral evolution during HIV-2 infection.

14. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.

15. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.

16. Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo.

17. Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: differential mechanism for immunoprotection.

18. Viral dynamics of primary HIV-1 infection in Senegal, West Africa.

19. Associations between MHC class I and susceptibility to HIV-2 disease progression.

20. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals.

21. Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay.

22. Interaction with human immunodeficiency virus (HIV) type 2 predicts HIV type 1 genotype.

23. Genetic analysis of HIV type 2 in monotypic and dual HIV infections.

24. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo.

25. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

26. Relation between HIV-2 proviral load and CD4+ lymphocyte count differs in monotypic and dual HIV infections.

27. HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts.

28. Sexually transmitted diseases and risk of HIV infection in men attending a sexually transmitted diseases clinic in Dakar, Senegal.

29. Accuracy of two enzyme immunoassays and cell culture in the detection of Chlamydia trachomatis in low and high risk populations in Senegal.

Catalog

Books, media, physical & digital resources